Contemporary perspectives in COPD: Patient burden, the role of gender and trajectories of multimorbidity

Sara C Buttery, Maéva Zysman, Sigrid A A Vikjord, Nicholas S Hopkinson, Christine Jenkins, Lowie E G W Vanfleteren, Sara C Buttery, Maéva Zysman, Sigrid A A Vikjord, Nicholas S Hopkinson, Christine Jenkins, Lowie E G W Vanfleteren

Abstract

An individual's experience of COPD is determined by many factors in addition to the pathological features of chronic bronchitis and emphysema and the symptoms that derive directly from them. Multimorbidity is the norm rather than the exception, so most people with COPD are living with a range of other medical problems which can decrease overall quality of life. COPD is caused by the inhalation of noxious particles or gases, in particular tobacco smoke, but also by early life disadvantage impairing lung development and by occupations where inhaled exposures are common (e.g. industrial, farming and cleaning work). Wealthy people are therefore relatively protected from developing COPD and people who do develop the condition may have reduced resources to cope. COPD is also no longer a condition that predominantly affects men. The prevalence of COPD among women has equalled that of men since 2008 in many high-income countries, due to increased exposure to tobacco, and in low-income countries due to biomass fuels. COPD is one of the leading causes of death in women in the USA, and death rates attributed to COPD in women in some countries are predicted to overtake those of men in the next decade. Many factors contribute to this phenomenon, but in addition to socioeconomic and occupational factors, there is increasing evidence of a higher susceptibility of females to smoking and pollutants. Quality of life is also more significantly impaired in women. Although most medications (bronchodilators and inhaled corticosteroids) used to treat COPD demonstrate similar trends for exacerbation prevention and lung function improvement in men and women, this is an understudied area and clinical trials frequently have a preponderance of males. A better understanding of gender-based predictors of efficacy of all therapeutic interventions is crucial for comprehensive patient care. There is an urgent need to recognize the increasing burden of COPD in women and to facilitate global improvements in disease prevention and management in this specific population. Many individuals with COPD follow a trajectory of both lung function decline and also multimorbidity. Unfavourable lung function trajectories throughout life have implications for later development of other chronic diseases. An enhanced understanding of the temporal associations underlying the development of coexisting diseases is a crucial first step in unravelling potential common disease pathways. Lessons can be learned from exploring disease trajectories of other NCD as well as multimorbidity development. Further research will be essential to explain how early life risk factors commonly influence trajectories of COPD and other diseases, how different diseases develop in relation to each other in a temporal way and how this ultimately leads to different multimorbidity patterns in COPD. This review integrates new knowledge and ideas pertaining to three broad themes (i) the overall burden of disease in COPD, (ii) an unappreciated high burden in women and (iii) the contrast of COPD trajectories and different multimorbidity patterns with trajectories of other NCD. The underlying pathology of COPD is largely irreversible, but many factors noted in the review are potentially amenable to intervention. Health and social care systems need to ensure that effective treatment is accessible to all people with the condition. Preventive strategies and treatments that alter the course of disease are crucial, particularly for patients with COPD as one of many problems.

Keywords: frailty; inequality; patient perspective; patient-reported outcome measure; symptoms.

© 2021 Asian Pacific Society of Respirology.

References

REFERENCES

    1. GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir. Med. 2017; 5: 691-706.
    1. Burney P. Chronic respiratory disease - the acceptable epidemic? Clin. Med. 2017; 17: 29-32.
    1. World Health Organization. Global progress report on implementation of the WHO Framework Convention on Tobacco Control 2018. 2018. [Accessed 1 Feb 2021]. Available from URL:
    1. Doiron D, de Hoogh K, Probst-Hensch N, Fortier I, Cai Y, De Matteis S, Hansell AL. Air pollution, lung function and COPD: results from the population-based UK Biobank study. Eur. Respir. J. 2019; 54: 1802140.
    1. Kurmi OP, Semple S, Simkhada P, Smith WCS, Ayres JG. COPD and chronic bronchitis risk of indoor air pollution from solid fuel: a systematic review and meta-analysis. Thorax 2010; 65: 221-8.
    1. Quaderi SA, Hurst JR. The unmet global burden of COPD. Glob. Health Epidemiol. Genom. 2018; 3: e4.
    1. Williams S, Sheikh A, Campbell H, Fitch N, Griffiths C, Heyderman RS, Jordan RE, Katikireddi SV, Tsiligianni I, Obasi A. Respiratory research funding is inadequate, inequitable, and a missed opportunity. Lancet Respir. Med. 2020; 8: e67-8.
    1. Hopkinson N. Respiratory disease is in the long term plan. BMJ 2019; 364: l413.
    1. Philip K, Gaduzo S, Rogers J, Laffan M, Hopkinson NS. Patient experience of COPD care: outcomes from the British Lung Foundation Patient Passport. BMJ Open Respir. Res. 2019; 6: e000478.
    1. Elbehairy AF, Quint JK, Rogers J, Laffan M, Polkey MI, Hopkinson NS. Patterns of breathlessness and associated consulting behaviour: results of an online survey. Thorax 2019; 74: 814-7.
    1. Jones RCM, Price D, Ryan D, Sims EJ, von Ziegenweidt J, Mascarenhas L, Burden A, Halpin DMG, Winter R, Hill S et al. Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort. Lancet Respir. Med. 2014; 2: 267-76.
    1. Royal College of Physicians. National COPD primary care audit 2014-15 national report (Wales). 2017. [Accessed 24 Mar 2017.] Available from URL:
    1. Whittaker HR, Connell O, Campbell J, Elbehairy AF, Hopkinson NS, Quint JK. Eligibility for lung volume reduction surgery in patients with COPD identified in a UK primary care setting. Chest 2020; 157: 276-85.
    1. Buttery S, Lewis A, Oey I, Hargrave J, Waller D, Steiner M, Shah PL, Kemp SV, Jordan S, Hopkinson NS. Patient experience of lung volume reduction procedures for emphysema: a qualitative service improvement project. ERJ Open Res. 2017; 3: 00031-2017.
    1. Buttery SC, Lewis A, Kemp SV, Banya W, Quint JK, Steiner MC, Hopkinson NS. Lung volume reduction eligibility in patients with COPD completing pulmonary rehabilitation: results from the UK National Asthma and COPD Audit Programme. BMJ Open 2020; 10: e040942.
    1. Miravitlles M, Ribera A. Understanding the impact of symptoms on the burden of COPD. Respir. Res. 2017; 18: 67.
    1. Gardener AC, Ewing G, Kuhn I, Farquhar M. Support needs of patients with COPD: a systematic literature search and narrative review. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 1021-35.
    1. Gershon AS, Dolmage TE, Stephenson A, Jackson B. Chronic obstructive pulmonary disease and socioeconomic status: a systematic review. COPD 2012; 9: 216-26.
    1. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012; 380: 37-43.
    1. Vanfleteren LE, Spruit MA, Groenen M, Gaffron S, van Empel VP, Bruijnzeel PL, Rutten EP, Op 't Roodt J, Wouters EF, Franssen FM. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2013; 187: 728-35.
    1. Hopkinson NS, Molyneux A, Pink J, Harrisingh MC. Chronic obstructive pulmonary disease: diagnosis and management: summary of updated NICE guidance. BMJ 2019; 366: l4486.
    1. Hodson M, Roberts CM, Andrew S, Graham L, Jones PW, Yorke J. Development and first validation of a patient-reported experience measure in chronic obstructive pulmonary disease (PREM-C9). Thorax 2019; 74: 600-3.
    1. Gimeno-Santos E, Raste Y, Demeyer H, Louvaris Z, de Jong C, Rabinovich RA, Hopkinson NS, Polkey MI, Vogiatzis I, Tabberer M et al.; PROactive Consortium. The PROactive instruments to measure physical activity in patients with chronic obstructive pulmonary disease. Eur. Respir. J. 2015; 46: 988-1000.
    1. Dodd JW, Hogg L, Nolan J, Jefford H, Grant A, Lord VM, Falzon C, Garrod R, Lee C, Polkey MI et al. The COPD assessment test (CAT): response to pulmonary rehabilitation. A multicentre, prospective study. Thorax 2011; 66: 425-9.
    1. Kelly JL, Bamsey O, Smith C, Lord VM, Shrikrishna D, Jones PW, Polkey MI, Hopkinson NS. Health status assessment in routine clinical practice: the chronic obstructive pulmonary disease assessment test score in outpatients. Respiration 2012; 84: 193-9.
    1. Miravitlles M, Worth H, Soler Cataluña JJ, Price D, De Benedetto F, Roche N, Godtfredsen NS, van der Molen T, Löfdahl C-G, Padullés L et al. Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study. Respir. Res. 2014; 15: 122-2.
    1. Rabe KF. Improving dyspnea in chronic obstructive pulmonary disease: optimal treatment strategies. Proc. Am. Thorac. Soc. 2006; 3: 270-5.
    1. Kardos P, Vogelmeier C, Worth H, Buhl R, Lossi NS, Mailänder C, Criée C-P. A two-year evaluation of the ‘real life’ impact of COPD on patients in Germany: the DACCORD observational study. Respir. Med. 2017; 124: 57-64.
    1. Shrikrishna D, Hopkinson NS. Chronic obstructive pulmonary disease: consequences beyond the lung. Clin. Med. (Lond.) 2012; 12: 71-4.
    1. Gimeno-Santos E, Frei A, Steurer-Stey C, de Batlle J, Rabinovich RA, Raste Y, Hopkinson NS, Polkey MI, van Remoortel H, Troosters T et al.; PROactive Consortium. Determinants and outcomes of physical activity in patients with COPD: a systematic review. Thorax 2014; 69: 731-9.
    1. Hopkinson NS, Polkey MI. Does physical inactivity cause chronic obstructive pulmonary disease? Clin. Sci. (Lond.) 2010; 118: 565-72.
    1. Shrikrishna D, Patel M, Tanner RJ, Seymour JM, Connolly BA, Puthucheary ZA, Walsh SL, Bloch SA, Sidhu PS, Hart N et al. Quadriceps wasting and physical inactivity in patients with COPD. Eur. Respir. J. 2012; 40: 1115-22.
    1. Strain T, Wijndaele K, Dempsey PC, Sharp SJ, Pearce M, Jeon J, Lindsay T, Wareham N, Brage S. Wearable-device-measured physical activity and future health risk. Nat. Med. 2020; 26: 1385-91.
    1. Waschki B, Kirsten A, Holz O, Müller KC, Meyer T, Watz H, Magnussen H. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest 2011; 140: 331-42.
    1. Aitsi-Selmi A, Hopkinson NS. Breathlessness, physical activity and sustainability of healthcare. Eur. Respir. J. 2015; 45: 284-5.
    1. Boutou AK, Karrar S, Hopkinson NS, Polkey MI. Anemia and survival in chronic obstructive pulmonary disease: a dichotomous rather than a continuous predictor. Respiration 2013; 85: 126-31.
    1. Johnson MJ, Yorke J, Hansen-Flaschen J, Lansing R, Ekström M, Similowski T, Currow DC. Towards an expert consensus to delineate a clinical syndrome of chronic breathlessness. Eur. Respir. J. 2017; 49: 1602277.
    1. Galbraith S, Fagan P, Perkins P, Lynch A, Booth S. Does the use of a handheld fan improve chronic dyspnea? A randomized, controlled, crossover trial. J. Pain Symptom Manage. 2010; 39: 831-8.
    1. Luckett T, Phillips J, Johnson MJ, Farquhar M, Swan F, Assen T, Bhattarai P, Booth S. Contributions of a hand-held fan to self-management of chronic breathlessness. Eur. Respir. J. 2017; 50: 1700262.
    1. Smallwood N, Le B, Currow D, Irving L, Philip J. Management of refractory breathlessness with morphine in patients with chronic obstructive pulmonary disease. Intern. Med. J. 2015; 45: 898-904.
    1. O'Donnell DE, Milne KM, James MD, de Torres JP, Neder JA. Dyspnea in COPD: new mechanistic insights and management implications. Adv. Ther. 2020; 37: 41-60.
    1. Harb N, Foster JM, Dobler CC. Patient-perceived treatment burden of chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; 12: 1641-52.
    1. Bourbeau J, Lavoie KL, Sedeno M, De Sousa D, Erzen D, Hamilton A, Maltais F, Troosters T, Leidy N. Behaviour-change intervention in a multicentre, randomised, placebo-controlled COPD study: methodological considerations and implementation. BMJ Open 2016; 6: e010109.
    1. Troosters T, Bourbeau J, Maltais F, Leidy N, Erzen D, De Sousa D, Korducki L, Hamilton A. Enhancing exercise tolerance and physical activity in COPD with combined pharmacological and non-pharmacological interventions: PHYSACTO randomised, placebo-controlled study design. BMJ Open 2016; 6: e010106.
    1. Mendoza L, Horta P, Espinoza J, Aguilera M, Balmaceda N, Castro A, Ruiz M, Diaz O, Hopkinson NS. Pedometers to enhance physical activity in COPD: a randomised controlled trial. Eur. Respir. J. 2015; 45: 347-54.
    1. Jones PW, Brusselle G, Dal Negro RW, Ferrer M, Kardos P, Levy ML, Perez T, Cataluña JJS, van der Molen T, Adamek L et al. Patient-centred assessment of COPD in primary care: experience from a cross-sectional study of health-related quality of life in Europe. Prim. Care Respir. J. 2012; 21: 329-36.
    1. Choate R, Pasquale CB, Parada NA, Prieto-Centurion V, Mularski RA, Yawn BP. The burden of cough and phlegm in people with COPD: a COPD patient-powered research network study. Chronic Obstr. Pulm. Dis. 2020; 7: 49-59.
    1. Cook N, Gey J, Oezel B, Mackay AJ, Kumari C, Kaur VP, Larkin N, Harte J, Vergara-Muro S, Gutzwiller FS. Impact of cough and mucus on COPD patients: primary insights from an exploratory study with an Online Patient Community. Int. J. Chron. Obstruct. Pulmon. Dis. 2019; 14: 1365-76.
    1. Lindberg A, Sawalha S, Hedman L, Larsson LG, Lundbäck B, Rönmark E. Subjects with COPD and productive cough have an increased risk for exacerbations and death. Respir. Med. 2015; 109: 88-95.
    1. Battaglia S, Benfante A, Principe S, Basile L, Scichilone N. Urinary incontinence in chronic obstructive pulmonary disease: a common co-morbidity or a typical adverse effect? Drugs Aging 2019; 36: 799-806.
    1. Ward N. The Leicester Cough Questionnaire. J. Physiother. 2016; 62: 53.
    1. Barker R, Laverty AA, Hopkinson NS. Adjuncts for sputum clearance in COPD: clinical consensus versus actual use. BMJ Open Respir. Res. 2017; 4: e000226.
    1. Alghamdi SM, Barker RE, Alsulayyim ASS, Alasmari AM, Banya WAS, Polkey MI, Birring SS, Hopkinson NS. Use of oscillatory positive expiratory pressure (OPEP) devices to augment sputum clearance in COPD: a systematic review and meta-analysis. Thorax 2020; 75: 855-63.
    1. Mohandas H, Jaganathan SK, Mani MP, Ayyar M, Rohini Thevi GV. Cancer-related fatigue treatment: an overview. J. Cancer Res. Ther. 2017; 13: 916-29.
    1. Goërtz YMJ, Spruit MA, Van 't Hul AJ, Peters JB, Van Herck M, Nakken N, Djamin RS, Burtin C, Thong MSY, Coors A et al. Fatigue is highly prevalent in patients with COPD and correlates poorly with the degree of airflow limitation. Ther. Adv. Respir. Dis. 2019; 13: 1753466619878128.
    1. Bültmann U, Kant I, Kasl SV, Beurskens AJHM, van den Brandt PA. Fatigue and psychological distress in the working population: psychometrics, prevalence, and correlates. J. Psychosom. Res. 2002; 52: 445-52.
    1. Swain MG. Fatigue in chronic disease. Clin. Sci. (Lond.) 2000; 99: 1-8.
    1. Kouijzer M, Brusse-Keizer M, Bode C. COPD-related fatigue: impact on daily life and treatment opportunities from the patient's perspective. Respir. Med. 2018; 141: 47-51.
    1. Peters JB, Heijdra YF, Daudey L, Boer LM, Molema J, Dekhuijzen PN, Schermer TR, Vercoulen JH. Course of normal and abnormal fatigue in patients with chronic obstructive pulmonary disease, and its relationship with domains of health status. Patient Educ. Couns. 2011; 85: 281-5.
    1. Rennard S, Decramer M, Calverley PMA, Pride NB, Soriano JB, Vermeire PA, Vestbo J. Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur. Respir. J. 2002; 20: 799-805.
    1. McNicholas WT, Verbraecken J, Marin JM. Sleep disorders in COPD: the forgotten dimension. Eur. Respir. Rev. 2013; 22: 365-75.
    1. Nunes DM, Mota RM, de Pontes Neto OL, Pereira ED, de Bruin VM, de Bruin PF. Impaired sleep reduces quality of life in chronic obstructive pulmonary disease. Lung 2009; 187: 159-63.
    1. Omachi TA, Blanc PD, Claman DM, Chen H, Yelin EH, Julian L, Katz PP. Disturbed sleep among COPD patients is longitudinally associated with mortality and adverse COPD outcomes. Sleep Med. 2012; 13: 476-83.
    1. Olaithe M, Bucks RS, Hillman DR, Eastwood PR. Cognitive deficits in obstructive sleep apnea: insights from a meta-review and comparison with deficits observed in COPD, insomnia, and sleep deprivation. Sleep Med. Rev. 2018; 38: 39-49.
    1. Lenferink A, Brusse-Keizer M, van der Valk P, Frith PA, Zwerink M, Monninkhof EM, van der Palen J, Effing TW. Self-management interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2017; 8: CD011682.
    1. Lewthwaite H, Effing TW, Olds T, Williams MT. Physical activity, sedentary behaviour and sleep in COPD guidelines: a systematic review. Chron. Respir. Dis. 2017; 14: 231-44.
    1. McNicholas WT, Hansson D, Schiza S, Grote L. Sleep in chronic respiratory disease: COPD and hypoventilation disorders. Eur. Respir. Rev. 2019; 28: 190064.
    1. Lal C, Kumbhare S, Strange C. Prevalence of self-reported sleep problems amongst adults with obstructive airway disease in the NHANES cohort in the United States. Sleep Breath. 2020; 24: 985-93.
    1. Maddocks M, Shrikrishna D, Vitoriano S, Natanek SA, Tanner RJ, Hart N, Kemp PR, Moxham J, Polkey MI, Hopkinson NS. Skeletal muscle adiposity is associated with physical activity, exercise capacity and fibre shift in COPD. Eur. Respir. J. 2014; 44: 1188-98.
    1. Sadaka AS, Faisal A, Khalil YM, Mourad SM, Zidan MH, Polkey MI, Hopkinson NS. Reduced skeletal muscle endurance and ventilatory efficiency during exercise in adult smokers without airflow obstruction. J. Appl. Physiol. (1985) 2021. DOI: 10.1152/japplphysiol.00762.2020 [Epub ahead of print].
    1. Hopkinson NS, Sharshar T, Ross ET, Nickol AH, Dayer MJ, Porcher R, Jonville S, Moxham J, Polkey MI. Corticospinal control of respiratory muscles in chronic obstructive pulmonary disease. Respir. Physiol. Neurobiol. 2004; 141: 1-12.
    1. Jackson AS, Shrikrishna D, Kelly JL, Kemp SV, Hart N, Moxham J, Polkey MI, Kemp P, Hopkinson NS. Vitamin D and skeletal muscle strength and endurance in COPD. Eur. Respir. J. 2013; 41: 309-16.
    1. Patel MS, Natanek SA, Stratakos G, Pascual S, Martínez-Llorens J, Disano L, Terzis G, Hopkinson NS, Gea J, Vogiatzis I et al. Vastus lateralis fiber shift is an independent predictor of mortality in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2014; 190: 350-2.
    1. Boutou AK, Raste Y, Demeyer H, Troosters T, Polkey MI, Vogiatzis I, Louvaris Z, Rabinovich RA, van der Molen T, Garcia-Aymerich J et al. Progression of physical inactivity in COPD patients: the effect of time and climate conditions - a multicenter prospective cohort study. Int. J. Chron. Obstruct. Pulmon. Dis. 2019; 14: 1979-92.
    1. Garcia-Aymerich J, Puhan MA, Corriol-Rohou S, de Jong C, Demeyer H, Dobbels F, Erzen D, Frei A, Gimeno-Santos E, Hopkinson NS et al. Validity and responsiveness of the Daily- and Clinical visit-PROactive Physical Activity in COPD (D-PPAC and C-PPAC) instruments. Thorax 2021; 76: 228-38.
    1. Patel MS, Mohan D, Andersson YM, Baz M, Samantha Kon SC, Canavan JL, Jackson SG, Clark AL, Hopkinson NS, Natanek SA et al. Phenotypic characteristics associated with reduced short physical performance battery score in COPD. Chest 2014; 145: 1016-24.
    1. Brighton LJ, Bristowe K, Bayly J, Ogden M, Farquhar M, Evans CJ, Man WD, Maddocks M. Experiences of pulmonary rehabilitation in people living with COPD and frailty: a qualitative interview study. Ann. Am. Thorac. Soc. 2020; 17: 1213-21.
    1. Suissa S, Dell'Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 2012; 67: 957-63.
    1. Zwerink M, Brusse-Keizer M, van der Valk P, Zielhuis GA, Monninkhof EM, van der Palen J, Frith PA, Effing T. Self management for patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2014; 2014: CD002990.
    1. Vogelmeier CF, Román-Rodríguez M, Singh D, Han MK, Rodríguez-Roisin R, Ferguson GT. Goals of COPD treatment: focus on symptoms and exacerbations. Respir. Med. 2020; 166: 105938.
    1. Shepperd S, Doll H, Angus RM, Clarke MJ, Iliffe S, Kalra L, Ricauda NA, Wilson AD. Admission avoidance hospital at home. Cochrane Database Syst. Rev. 2016; 9: CD007491.
    1. Pollok J, van Agteren JE, Esterman AJ, Carson-Chahhoud KV. Psychological therapies for the treatment of depression in chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2019; 3: CD012347.
    1. Kendrick T, Pilling S. Common mental health disorders - identification and pathways to care: NICE clinical guideline. Br. J. Gen. Pract. 2012; 62: 47-9.
    1. Ma RC, Yin YY, Wang YQ, Liu X, Xie J. Effectiveness of cognitive behavioural therapy for chronic obstructive pulmonary disease patients: a systematic review and meta-analysis. Complement. Ther. Clin. Pract. 2020; 38: 101071.
    1. Coventry PA, Hind D. Comprehensive pulmonary rehabilitation for anxiety and depression in adults with chronic obstructive pulmonary disease: systematic review and meta-analysis. J. Psychosom. Res. 2007; 63: 551-65.
    1. Boutou AK, Tanner RJ, Lord VM, Hogg L, Nolan J, Jefford H, Corner EJ, Falzon C, Lee C, Garrod R et al. An evaluation of factors associated with completion and benefit from pulmonary rehabilitation in COPD. BMJ Open Respir. Res. 2014; 1: e000051.
    1. Zhang WZ. The origins of chronic obstructive pulmonary disease: sometimes the journey matters more than the destination. Am. J. Respir. Crit. Care Med. 2020; 202: 159-61.
    1. Bu F, Philip K, Fancourt D. Social isolation and loneliness as risk factors for hospital admissions for respiratory disease among older adults. Thorax 2020; 75: 597-9.
    1. Steptoe A, Shankar A, Demakakos P, Wardle J. Social isolation, loneliness, and all-cause mortality in older men and women. Proc. Natl. Acad. Sci. U. S. A. 2013; 110: 5797-801.
    1. Philip KEJ, Polkey MI, Hopkinson NS, Steptoe A, Fancourt D. Social isolation, loneliness and physical performance in older-adults: fixed effects analyses of a cohort study. Sci. Rep. 2020; 10: 13908.
    1. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, Holden KA, Read JM, Dondelinger F, Carson G et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ 2020; 369: m1985.
    1. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, Curtis HJ, Mehrkar A, Evans D, Inglesby P et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020; 584: 430-6.
    1. Demeyer H, Louvaris Z, Frei A, Rabinovich RA, de Jong C, Gimeno-Santos E, Loeckx M, Buttery SC, Rubio N, Van der Molen T et al.; Mr Papp PROactive Study Group and the PROactive Consortium. Physical activity is increased by a 12-week semiautomated telecoaching programme in patients with COPD: a multicentre randomised controlled trial. Thorax 2017; 72: 415-23.
    1. Loeckx M, Rabinovich RA, Demeyer H, Louvaris Z, Tanner R, Rubio N, Frei A, De Jong C, Gimeno-Santos E, Rodrigues FM et al. Smartphone-based physical activity telecoaching in chronic obstructive pulmonary disease: mixed-methods study on patient experiences and lessons for implementation. JMIR Mhealth Uhealth 2018; 6: e200.
    1. Polgar O, Aljishi M, Barker RE, Patel S, Walsh JA, Kon SSC, Man WDC, Nolan CM. Digital habits of PR service-users: implications for home-based interventions during the COVID-19 pandemic. Chron. Respir. Dis. 2020; 17: 1479973120936685.
    1. Epiphaniou E, Shipman C, Harding R, Mason B, Murray SA, Higginson IJ, Daveson BA. Coordination of end-of-life care for patients with lung cancer and those with advanced COPD: are there transferable lessons? A longitudinal qualitative study. Prim. Care Respir. J. 2014; 23: 46-51.
    1. Hopkinson NS. Caring about what happens to people with COPD. Thorax 2017; 72: 683-5.
    1. Zoumot Z, Jordan S, Hopkinson NS. Emphysema: time to say farewell to therapeutic nihilism. Thorax 2014; 69: 973-5.
    1. Hopkinson NS, Baxter N; London Respiratory Network. Breathing SPACE - a practical approach to the breathless patient. NPJ Prim. Care Respir. Med. 2017; 27: 5.
    1. Clark SJ, Zoumot Z, Bamsey O, Polkey MI, Dusmet M, Lim E, Jordan S, Hopkinson NS. Surgical approaches for lung volume reduction in emphysema. Clin. Med. (Lond.) 2014; 14: 122-7.
    1. Hopkinson NS. Lung volume reduction for emphysema comes of age. BMJ 2021; 372: n14.
    1. Hopkinson NS. Lung volume reduction: apex treatments and the ecology of chronic obstructive pulmonary disease care. Am. J. Respir. Crit. Care Med. 2019; 200: 1329-31.
    1. Izquierdo JL, Morena D, González Y, Paredero JM, Pérez B, Graziani D, Gutiérrez M, Rodríguez JM. Clinical management of COPD in a real-world setting. A big data analysis. Arch. Bronconeumol. 2021; 57: 94-100.
    1. Lewis A, Cave P, Stern M, Welch L, Taylor K, Russell J, Doyle AM, Russell AM, McKee H, Clift S et al. Singing for Lung Health - a systematic review of the literature and consensus statement. NPJ Prim. Care Respir. Med. 2016; 26: 16080.
    1. Philip K, Lewis A, Hopkinson NS. Music and dance in chronic lung disease. Breathe (Sheff.) 2019; 15: 116-20.
    1. Lewis A, Hopkinson NS. Tai Chi Movements for Wellbeing - evaluation of a British Lung Foundation pilot. Perspect. Public Health 2020; 140: 172-80.
    1. Zafeiridou M, Hopkinson NS, Voulvoulis N. Cigarette smoking: an assessment of tobacco's global environmental footprint across its entire supply chain. Environ. Sci. Technol. 2018; 52: 8087-94.
    1. Ntritsos G, Franek J, Belbasis L, Christou MA, Markozannes G, Altman P, Fogel R, Sayre T, Ntzani EE, Evangelou E. Gender-specific estimates of COPD prevalence: a systematic review and meta-analysis. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 1507-14.
    1. Centers for Disease Control and Prevention. Leading causes of death-all races and origins-females - United States, 2017. Women's Health, CDC, 2020.
    1. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007; 370: 765-73.
    1. Jenkins CR, Chapman KR, Donohue JF, Roche N, Tsiligianni I, Han MK. Improving the management of COPD in women. Chest 2017; 151: 686-96.
    1. Chapman KR, Tashkin DP, Pye DJ. Gender bias in the diagnosis of COPD. Chest 2001; 119: 1691-5.
    1. Lamprecht B, McBurnie MA, Vollmer WM, Gudmundsson G, Welte T, Nizankowska-Mogilnicka E, Studnicka M, Bateman E, Anto JM, Burney P et al. COPD in never smokers: results from the population-based burden of obstructive lung disease study. Chest 2011; 139: 752-63.
    1. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741-50.
    1. Watson L, Vonk JM, Löfdahl CG, Pride NB, Pauwels RA, Laitinen LA, Schouten JP, Postma DS. Predictors of lung function and its decline in mild to moderate COPD in association with gender: results from the Euroscop study. Respir. Med. 2006; 100: 746-53.
    1. Silverman M, Pedersen S, Grigg J. Measurement of airway inflammation in children. Introduction. Am. J. Respir. Crit. Care Med. 2000; 162: S1.
    1. Lange P, Celli B, Agusti A, Boje Jensen G, Divo M, Faner R, Guerra S, Marott JL, Martinez FD, Martinez-Camblor P et al. Lung-function trajectories leading to chronic obstructive pulmonary disease. N. Engl. J. Med. 2015; 373: 111-22.
    1. Amaral AFS, Strachan DP, Burney PGJ, Jarvis DL. Female smokers are at greater risk of airflow obstruction than male smokers. UK Biobank. Am. J. Respir. Crit. Care Med. 2017; 195: 1226-35.
    1. Han MK, Postma D, Mannino DM, Giardino ND, Buist S, Curtis JL, Martinez FJ. Gender and chronic obstructive pulmonary disease: why it matters. Am. J. Respir. Crit. Care Med. 2007; 176: 1179-84.
    1. Sørheim IC, Johannessen A, Gulsvik A, Bakke PS, Silverman EK, DeMeo DL. Gender differences in COPD: are women more susceptible to smoking effects than men? Thorax 2010; 65: 480-5.
    1. Jordan RE, Miller MR, Lam KB, Cheng KK, Marsh J, Adab P. Sex, susceptibility to smoking and chronic obstructive pulmonary disease: the effect of different diagnostic criteria. Analysis of the Health Survey for England. Thorax 2012; 67: 600-5.
    1. Wang S, Gong W, Tian Y. Voluntary pulmonary function screening identifies high rates of undiagnosed asymptomatic chronic obstructive pulmonary disease. Chron. Respir. Dis. 2016; 13: 137-43.
    1. Kurmi OP, Li L, Wang J, Millwood IY, Chen J, Collins R, Guo Y, Bian Z, Li J, Chen B et al. COPD and its association with smoking in the Mainland China: a cross-sectional analysis of 0.5 million men and women from ten diverse areas. Int. J. Chron. Obstruct. Pulmon. Dis. 2015; 10: 655-65.
    1. Ulrick C. Smoking and mortality in women: "smoke like a man, die (at least) like a man". Eur. Respir. Monogr. 2003; 25. DOI: 10.1183/1025448x.00025009
    1. Downs SH, Brändli O, Zellweger J-P, Schindler C, Künzli N, Gerbase MW, Burdet L, Bettschart R, Zemp E, Frey M et al.; SAPALDIA Team. Accelerated decline in lung function in smoking women with airway obstruction: SAPALDIA 2 cohort study. Respir. Res. 2005; 6: 45.
    1. Gershon AS, Warner L, Cascagnette P, Victor JC, To T. Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study. Lancet 2011; 378: 991-6.
    1. Blanc PD, Iribarren C, Trupin L, Earnest G, Katz PP, Balmes J, Sidney S, Eisner MD. Occupational exposures and the risk of COPD: dusty trades revisited. Thorax 2009; 64: 6-12.
    1. Dumas O, Varraso R, Boggs KM, Quinot C, Zock J-P, Henneberger PK, Speizer FE, Le Moual N, Camargo CA Jr. Association of occupational exposure to disinfectants with incidence of chronic obstructive pulmonary disease among US female nurses. JAMA Netw. Open 2019; 2: e1913563.
    1. Eduard W, Pearce N, Douwes J. Chronic bronchitis, COPD, and lung function in farmers: the role of biological agents. Chest 2009; 136: 716-25.
    1. Rinsky JL, Richardson DB, Kreiss K, Nylander-French L, Beane Freeman LE, London SJ, Henneberger PK, Hoppin JA. Animal production, insecticide use and self-reported symptoms and diagnoses of COPD, including chronic bronchitis, in the Agricultural Health Study. Environ. Int. 2019; 127: 764-72.
    1. Alif SM, Dharmage S, Benke G, Dennekamp M, Burgess J, Perret JL, Lodge C, Morrison S, Johns DP, Giles G et al. Occupational exposure to solvents and lung function decline: a population based study. Thorax 2019; 74: 650-8.
    1. Torén K, Järvholm B. Effect of occupational exposure to vapors, gases, dusts, and fumes on COPD mortality risk among Swedish construction workers: a longitudinal cohort study. Chest 2014; 145: 992-7.
    1. Siddharthan T, Grigsby MR, Goodman D, Chowdhury M, Rubinstein A, Irazola V, Gutierrez L, Miranda JJ, Bernabe-Ortiz A, Alam D et al. Association between household air pollution exposure and chronic obstructive pulmonary disease outcomes in 13 low- and middle-income country settings. Am. J. Respir. Crit. Care Med. 2018; 197: 611-20.
    1. Ramírez-Venegas A, Velázquez-Uncal M, Pérez-Hernández R, Guzmán-Bouilloud NE, Falfán-Valencia R, Mayar-Maya ME, Aranda-Chávez A, Sansores RH. Prevalence of COPD and respiratory symptoms associated with biomass smoke exposure in a suburban area. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 1727-34.
    1. Camp PG, Ramirez-Venegas A, Sansores RH, Alva LF, McDougall JE, Sin DD, Paré PD, Müller NL, Silva CIS, Rojas CE et al. COPD phenotypes in biomass smoke- versus tobacco smoke-exposed Mexican women. Eur. Respir. J. 2014; 43: 725-34.
    1. Tam A, Churg A, Wright JL, Zhou S, Kirby M, Coxson HO, Lam S, Man SF, Sin DD. Sex differences in airway remodeling in a mouse model of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2016; 193: 825-34.
    1. Roberts NJ, Patel IS, Partridge MR. The diagnosis of COPD in primary care; gender differences and the role of spirometry. Respir. Med. 2016; 111: 60-3.
    1. Wheaton AG, Pleasants RA, Croft JB, Ohar JA, Heidari K, Mannino DM, Liu Y, Strange C. Gender and asthma-chronic obstructive pulmonary disease overlap syndrome. J. Asthma 2016; 53: 720-31.
    1. Naberan K, Azpeitia A, Cantoni J, Miravitlles M. Impairment of quality of life in women with chronic obstructive pulmonary disease. Respir. Med. 2012; 106: 367-73.
    1. Raherison C, Tillie-Leblond I, Prudhomme A, Taillé C, Biron E, Nocent-Ejnaini C, Mathieu B, Ostinelli J. Clinical characteristics and quality of life in women with COPD: an observational study. BMC Women's Health 2014; 14: 31.
    1. Zysman M, Burgel P-R, Court-Fortune I, Brinchault-Rabin G, Nesme-Meyer P, Surpas P, Deslée G, Perez T, Le Rouzic O, Jebrak G et al.; Initiatives BPCO Scientific Committee and Investigators. Relationship between gender and survival in a real-life cohort of patients with COPD. Respir. Res. 2019; 20: 191.
    1. Roche N, Deslée G, Caillaud D, Brinchault G, Court-Fortune I, Nesme-Meyer P, Surpas P, Escamilla R, Perez T, Chanez P et al.; INITIATIVES BPCO Scientific Committee. Impact of gender on COPD expression in a real-life cohort. Respir. Res. 2014; 15: 20.
    1. Prescott E, Bjerg AM, Andersen PK, Lange P, Vestbo J. Gender difference in smoking effects on lung function and risk of hospitalization for COPD: results from a Danish longitudinal population study. Eur. Respir. J. 1997; 10: 822-7.
    1. Coxson HO, Dirksen A, Edwards LD, Yates JC, Agusti A, Bakke P, Calverley PM, Celli B, Crim C, Duvoix A et al. The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. Lancet Respir. Med. 2013; 1: 129-36.
    1. DeMeo DL, Ramagopalan S, Kavati A, Vegesna A, Han MK, Yadao A, Wilcox TK, Make BJ. Women manifest more severe COPD symptoms across the life course. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 3021-9.
    1. Stolz D, Kostikas K, Loefroth E, Fogel R, Gutzwiller FS, Conti V, Cao H, Clemens A. Differences in COPD exacerbation risk between women and men: analysis from the UK clinical practice research datalink data. Chest 2019; 156: 674-84.
    1. Molinari N, Chanez P, Roche N, Ahmed E, Vachier I, Bourdin A. Rising total costs and mortality rates associated with admissions due to COPD exacerbations. Respir. Res. 2016; 17: 149.
    1. Goto T, Yoshida K, Faridi MK, Camargo CA Jr, Hasegawa K. Contribution of social factors to readmissions within 30 days after hospitalization for COPD exacerbation. BMC Pulm. Med. 2020; 20: 107.
    1. Vestbo J, Prescott E, Lange P, Schnohr P, Jensen G. Vital prognosis after hospitalization for COPD: a study of a random population sample. Respir. Med. 1998; 92: 772-6.
    1. Ekström MP, Jogréus C, Ström KE. Comorbidity and sex-related differences in mortality in oxygen-dependent chronic obstructive pulmonary disease. PLoS One 2012; 7: e35806.
    1. Bade BC, DeRycke EC, Ramsey C, Skanderson M, Crothers K, Haskell S, Bean-Mayberry B, Brandt C, Bastian LA, Akgün KM. Sex differences in veterans admitted to the hospital for chronic obstructive pulmonary disease exacerbation. Ann. Am. Thorac. Soc. 2019; 16: 707-14.
    1. Roche N, Antoniadis A, Hess D, Li PZ, Kelkel E, Leroy S, Pison C, Burgel PR, Aguilaniu B. Are there specific clinical characteristics associated with physician's treatment choices in COPD? Respir. Res. 2019; 20: 189.
    1. Delgado A, Saletti-Cuesta L, López-Fernández LA, Gil-Garrido N, Luna Del Castillo JD. Gender inequalities in COPD decision-making in primary care. Respir. Med. 2016; 114: 91-6.
    1. Jia G, Lu M, Wu R, Chen Y, Yao W. Gender difference on the knowledge, attitude, and practice of COPD diagnosis and treatment: a national, multicenter, cross-sectional survey in China. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 3269-80.
    1. Aryal S, Diaz-Guzman E, Mannino DM. Influence of sex on chronic obstructive pulmonary disease risk and treatment outcomes. Int. J. Chron. Obstruct. Pulmon. Dis. 2014; 9: 1145-54.
    1. Lamprecht B, Soriano JB, Studnicka M, Kaiser B, Vanfleteren LE, Gnatiuc L, Burney P, Miravitlles M, García-Rio F, Akbari K et al. Determinants of underdiagnosis of COPD in national and international surveys. Chest 2015; 148: 971-85.
    1. Åberg J, Hasselgren M, Montgomery S, Lisspers K, Ställberg B, Janson C, Sundh J. Sex-related differences in management of Swedish patients with a clinical diagnosis of chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2019; 14: 961-9.
    1. Lisspers K, Larsson K, Janson C, Ställberg B, Tsiligianni I, Gutzwiller FS, Mezzi K, Bjerregaard BK, Jorgensen L, Johansson G. Gender differences among Swedish COPD patients: results from the ARCTIC, a real-world retrospective cohort study. NPJ Prim. Care Respir. Med. 2019; 29: 45.
    1. Henoch I, Strang S, Löfdahl CG, Ekberg-Jansson A. Management of COPD, equal treatment across age, gender, and social situation? A register study. Int. J. Chron. Obstruct. Pulmon. Dis. 2016; 11: 2681-90.
    1. Oshagbemi OA, Keene SJ, Driessen JHM, Jordan R, Wouters EFM, de Boer A, de Vries F, Franssen FME. Trends in moderate and severe exacerbations among COPD patients in the UK from 2005 to 2013. Respir. Med. 2018; 144: 1-6.
    1. Aryal S, Diaz-Guzman E, Mannino DM. COPD and gender differences: an update. Transl. Res. 2013; 162: 208-18.
    1. Bellocchia M, Masoero M, Ciuffreda A, Croce S, Vaudano A, Torchio R, Boita M, Bucca C. Predictors of cardiovascular disease in asthma and chronic obstructive pulmonary disease. Multidiscip. Respir. Med. 2013; 8: 58.
    1. Almagro P, López García F, Cabrera FJ, Montero L, Morchón D, Díez J, Soriano JB. Comorbidity and gender-related differences in patients hospitalized for COPD. The ECCO study. Respir. Med. 2010; 104: 253-9.
    1. Fernández-García S, Represas-Represas C, Ruano-Raviña A, Mosteiro-Añón M, Mouronte-Roibas C, Fernández-Villar A. Social profile of patients admitted for COPD exacerbations. A gender analysis. Arch. Bronconeumol. 2020; 56: 84-9.
    1. Castañ-Abad MT, Montserrat-Capdevila J, Godoy P, Marsal JR, Ortega M, Alsedà M, Barbé F. Diabetes as a risk factor for severe exacerbation and death in patients with COPD: a prospective cohort study. Eur. J. Public Health 2020; 30: 822-7.
    1. de Torres JP, Casanova C, Montejo de Garcini A, Aguirre-Jaime A, Celli BR. Gender and respiratory factors associated with dyspnea in chronic obstructive pulmonary disease. Respir. Res. 2007; 8: 18.
    1. Doucet M, Rochette L, Hamel D. Incidence, prevalence, and mortality trends in chronic obstructive pulmonary disease over 2001 to 2011: a public health point of view of the burden. Can. Respir. J. 2016; 2016: 7518287.
    1. Jain NK, Thakkar MS, Jain N, Rohan KA, Sharma M. Chronic obstructive pulmonary disease: does gender really matter? Lung India 2011; 28: 258-62.
    1. Gershon A, Hwee J, Victor JC, Wilton A, Wu R, Day A, To T. Mortality trends in women and men with COPD in Ontario, Canada, 1996-2012. Thorax 2015; 70: 121-6.
    1. Müllerova H, Maselli DJ, Locantore N, Vestbo J, Hurst JR, Wedzicha JA, Bakke P, Agusti A, Anzueto A. Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. Chest 2015; 147: 999-1007.
    1. Beeh KM, Glaab T, Stowasser S, Schmidt H, Fabbri LM, Rabe KF, Vogelmeier CF. Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial. Respir. Res. 2013; 14: 116.
    1. Celli B, Vestbo J, Jenkins CR, Jones PW, Ferguson GT, Calverley PM, Yates JC, Anderson JA, Willits LR, Wise RA. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. Am. J. Respir. Crit. Care Med. 2011; 183: 317-22.
    1. Sundh J, Johansson G, Larsson K, Lindén A, Löfdahl CG, Sandström T, Janson C. The phenotype of concurrent chronic bronchitis and frequent exacerbations in patients with severe COPD attending Swedish secondary care units. Int. J. Chron. Obstruct. Pulmon. Dis. 2015; 10: 2327-34.
    1. Golpe R, Mengual-Macenlle N, Martín-Robles I, Sanjuán-López P, Pérez de Llano LA. Prognostic value of multidimensional indices in ambulatory COPD patients. Eur. J. Intern. Med. 2015; 26: e38-9.
    1. McGarvey L, Lee AJ, Roberts J, Gruffydd-Jones K, McKnight E, Haughney J. Characterisation of the frequent exacerbator phenotype in COPD patients in a large UK primary care population. Respir. Med. 2015; 109: 228-37.
    1. Fuhrman C, Moutengou E, Roche N, Delmas MC. Prognostic factors after hospitalization for COPD exacerbation. Rev. Mal. Respir. 2017; 34: 1-18.
    1. Lindberg A, Larsson LG, Muellerova H, Rönmark E, Lundbäck B. Up-to-date on mortality in COPD - report from the OLIN COPD study. BMC Pulm. Med. 2012; 12: 1.
    1. Johansson G, Mushnikov V, Bäckström T, Engström A, Khalid JM, Wall J, Hoti F. Exacerbations and healthcare resource utilization among COPD patients in a Swedish registry-based nation-wide study. BMC Pulm. Med. 2018; 18: 17.
    1. Tsai CL, Clark S, Cydulka RK, Rowe BH, Camargo CA Jr. Factors associated with hospital admission among emergency department patients with chronic obstructive pulmonary disease exacerbation. Acad. Emerg. Med. 2007; 14: 6-14.
    1. Gershon A, Thiruchelvam D, Moineddin R, Zhao XY, Hwee J, To T. Forecasting hospitalization and emergency department visit rates for chronic obstructive pulmonary disease. A time-series analysis. Ann. Am. Thorac. Soc. 2017; 14: 867-73.
    1. Sundh J, Johansson G, Larsson K, Lindén A, Löfdahl CG, Janson C, Sandström T. Comorbidity and health-related quality of life in patients with severe chronic obstructive pulmonary disease attending Swedish secondary care units. Int. J. Chron. Obstruct. Pulmon. Dis. 2015; 10: 173-83.
    1. Martinez CH, Raparla S, Plauschinat CA, Giardino ND, Rogers B, Beresford J, Bentkover JD, Schachtner-Appel A, Curtis JL, Martinez FJ et al. Gender differences in symptoms and care delivery for chronic obstructive pulmonary disease. J. Women's Health (Larchmt) 2012; 21: 1267-74.
    1. Mamary AJ, Stewart JI, Kinney GL, Hokanson JE, Shenoy K, Dransfield MT, Foreman MG, Vance GB, Criner GJ. Race and gender disparities are evident in COPD underdiagnoses across all severities of measured airflow obstruction. Chronic Obstr. Pulm. Dis. 2018; 5: 177-84.
    1. Connett JE, Murray RP, Buist AS, Wise RA, Bailey WC, Lindgren PG, Owens GR. Changes in smoking status affect women more than men: results of the Lung Health Study. Am. J. Epidemiol. 2003; 157: 973-9.
    1. Tsiligianni I, Rodríguez MR, Lisspers K, LeeTan T, Infantino A. Call to action: improving primary care for women with COPD. NPJ Prim. Care Respir. Med. 2017; 27: 11.
    1. Pauwels RA, Löfdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N. Engl. J. Med. 1999; 340: 1948-53.
    1. Goodman DE, Israel E, Rosenberg M, Johnston R, Weiss ST, Drazen JM. The influence of age, diagnosis, and gender on proper use of metered-dose inhalers. Am. J. Respir. Crit. Care Med. 1994; 150: 1256-61.
    1. Wedzicha JA, Singh D, Tsiligianni I, Jenkins C, Fucile S, Fogel R, Shen S, Goyal P, Mezzi K, Kostikas K. Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study. Respir. Res. 2019; 20: 4.
    1. Tsiligianni I, Mezzi K, Fucile S, Kostikas K, Shen S, Banerji D, Fogel R. Response to indacaterol/glycopyrronium (IND/GLY) by sex in patients with COPD: a pooled analysis from the IGNITE program. COPD 2017; 14: 375-81.
    1. Sherrill DL, Holberg CJ, Enright PL, Lebowitz MD, Burrows B. Longitudinal analysis of the effects of smoking onset and cessation on pulmonary function. Am. J. Respir. Crit. Care Med. 1994; 149: 591-7.
    1. Xu X, Weiss ST, Rijcken B, Schouten JP. Smoking, changes in smoking habits, and rate of decline in FEV1: new insight into gender differences. Eur. Respir. J. 1994; 7: 1056-61.
    1. Pomerleau CS, Pomerleau OF, Garcia AW. Biobehavioral research on nicotine use in women. Br. J. Addict. 1991; 86: 527-31.
    1. Tashkin D, Kanner R, Bailey W, Buist S, Anderson P, Nides M, Gonzales D, Dozier G, Patel MK, Jamerson B. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001; 357: 1571-5.
    1. Moore SM, Kramer FM. Women's and men's preferences for cardiac rehabilitation program features. J. Cardiopulm. Rehabil. 1996; 16: 163-8.
    1. Agusti A, Noell G, Brugada J, Faner R. Lung function in early adulthood and health in later life: a transgenerational cohort analysis. Lancet Respir. Med. 2017; 5: 935-45.
    1. Agusti A, Faner R. Lung function trajectories in health and disease. Lancet Respir. Med. 2019; 7: 358-64.
    1. Vasquez MM, Zhou M, Hu C, Martinez FD, Guerra S. Low lung function in young adult life is associated with early mortality. Am. J. Respir. Crit. Care Med. 2017; 195: 1399-401.
    1. Young RP, Hopkins R, Eaton TE. Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes. Eur. Respir. J. 2007; 30: 616-22.
    1. Barker DJ. The developmental origins of chronic adult disease. Acta Paediatr. Suppl. 2004; 93: 26-33.
    1. Jornayvaz FR, Selz R, Tappy L, Theintz GE. Metabolism of oral glucose in children born small for gestational age: evidence for an impaired whole body glucose oxidation. Metabolism 2004; 53: 847-51.
    1. Cameron N, Demerath EW. Critical periods in human growth and their relationship to diseases of aging. Am. J. Phys. Anthropol. 2002; 119(Suppl. 35): 159-84.
    1. Janssen I, Leblanc AG. Systematic review of the health benefits of physical activity and fitness in school-aged children and youth. Int. J. Behav. Nutr. Phys. Act. 2010; 7: 40.
    1. Agusti A. 2020. The Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for prevention, diagnosis and management of COPD. 2020. [Accessed 1 Feb 2021]. Available from URL:
    1. Melen E, Guerra S. Recent advances in understanding lung function development. F1000Res. 2017; 6: 726.
    1. Bui DS, Lodge CJ, Burgess JA, Lowe AJ, Perret J, Bui MQ, Bowatte G, Gurrin L, Johns DP, Thompson BR et al. Childhood predictors of lung function trajectories and future COPD risk: a prospective cohort study from the first to the sixth decade of life. Lancet Respir. Med. 2018; 6: 535-44.
    1. Martinez FD. Early-life origins of chronic obstructive pulmonary disease. N. Engl. J. Med. 2016; 375: 871-8.
    1. McGeachie MJ, Yates KP, Zhou X, Guo F, Sternberg AL, Van Natta ML, Wise RA, Szefler SJ, Sharma S, Kho AT et al. Patterns of growth and decline in lung function in persistent childhood asthma. N. Engl. J. Med. 2016; 374: 1842-52.
    1. Schittny JC. Development of the lung. Cell Tissue Res. 2017; 367: 427-44.
    1. Burrows B, Cline MG, Knudson RJ, Taussig LM, Lebowitz MD. A descriptive analysis of the growth and decline of the FVC and FEV1. Chest 1983; 83: 717-24.
    1. Hall R, Hall IP, Sayers I. Genetic risk factors for the development of pulmonary disease identified by genome-wide association. Respirology 2019; 24: 204-14.
    1. Wain LV, Shrine N, Artigas MS, Erzurumluoglu AM, Noyvert B, Bossini-Castillo L, Obeidat M, Henry AP, Portelli MA, Hall RJ et al. Genome-wide association analyses for lung function and chronic obstructive pulmonary disease identify new loci and potential druggable targets. Nat. Genet. 2017; 49: 416-25.
    1. den Dekker HT, Burrows K, Felix JF, Salas LA, Nedeljkovic I, Yao J, Rifas-Shiman SL, Ruiz-Arenas C, Amin N, Bustamante M et al. Newborn DNA-methylation, childhood lung function, and the risks of asthma and COPD across the life course. Eur. Respir. J. 2019; 53: 1801795.
    1. Bermingham ML, Walker RM, Marioni RE, Morris SW, Rawlik K, Zeng Y, Campbell A, Redmond P, Whalley HC, Adams MJ et al. Identification of novel differentially methylated sites with potential as clinical predictors of impaired respiratory function and COPD. EBioMedicine 2019; 43: 576-86.
    1. Lahousse L. Epigenetic targets for lung diseases. EBioMedicine 2019; 43: 24-5.
    1. Jacob CM, Baird J, Barker M, Cooper C, Hanson M. The importance of a life course approach to health: chronic disease risk from preconception through adolescence and adulthood. WHO. 2017. [Accessed 1 Feb 2021]. Available from URL:
    1. Gibson AM, Doyle LW. Respiratory outcomes for the tiniest or most immature infants. Semin. Fetal Neonatal Med. 2014; 19: 105-11.
    1. Kajantie E, Strang-Karlsson S, Evensen KAI, Haaramo P. Adult outcomes of being born late preterm or early term - what do we know? Semin. Fetal Neonatal Med. 2019; 24: 66-83.
    1. Parkinson JR, Hyde MJ, Gale C, Santhakumaran S, Modi N. Preterm birth and the metabolic syndrome in adult life: a systematic review and meta-analysis. Pediatrics 2013; 131: e1240-63.
    1. de Jong F, Monuteaux MC, van Elburg RM, Gillman MW, Belfort MB. Systematic review and meta-analysis of preterm birth and later systolic blood pressure. Hypertension 2012; 59: 226-34.
    1. Carr H, Cnattingius S, Granath F, Ludvigsson JF, Edstedt Bonamy AK. Preterm birth and risk of heart failure up to early adulthood. J. Am. Coll. Cardiol. 2017; 69: 2634-42.
    1. Starr MC, Hingorani SR. Prematurity and future kidney health: the growing risk of chronic kidney disease. Curr. Opin. Pediatr. 2018; 30: 228-35.
    1. Barnes PJ. Mechanisms of development of multimorbidity in the elderly. Eur. Respir. J. 2015; 45: 790-806.
    1. Barker DJ. The origins of the developmental origins theory. J. Intern. Med. 2007; 261: 412-7.
    1. Wadhwa PD, Buss C, Entringer S, Swanson JM. Developmental origins of health and disease: brief history of the approach and current focus on epigenetic mechanisms. Semin. Reprod. Med. 2009; 27: 358-68.
    1. Frias AE, Grove KL. Obesity: a transgenerational problem linked to nutrition during pregnancy. Semin. Reprod. Med. 2012; 30: 472-8.
    1. Lunney JR, Lynn J, Foley DJ, Lipson S, Guralnik JM. Patterns of functional decline at the end of life. JAMA 2003; 289: 2387-92.
    1. Comstock Barker P, Scherer JS. Illness trajectories: description and clinical use #326. J. Palliat. Med. 2017; 20: 426-7.
    1. Niiranen TJ, Henglin M, Claggett B, Muggeo VMR, McCabe E, Jain M, Vasan RS, Larson MG, Cheng S. Trajectories of blood pressure elevation preceding hypertension onset: an analysis of the Framingham Heart Study Original Cohort. JAMA Cardiol. 2018; 3: 427-31.
    1. Stroustrup N, Anthony WE, Nash ZM, Gowda V, Gomez A, Lopez-Moyado IF, Apfeld J, Fontana W. The temporal scaling of Caenorhabditis elegans ageing. Nature 2016; 530: 103-7.
    1. Allen NB, Siddique J, Wilkins JT, Shay C, Lewis CE, Goff DC, Jacobs DR Jr, Liu K, Lloyd-Jones D. Blood pressure trajectories in early adulthood and subclinical atherosclerosis in middle age. JAMA 2014; 311: 490-7.
    1. Berenson GS. Childhood risk factors predict adult risk associated with subclinical cardiovascular disease. The Bogalusa Heart Study. Am. J. Cardiol. 2002; 90: 3L-7L.
    1. Hao G, Wang X, Treiber FA, Harshfield G, Kapuku G, Su S. Blood pressure trajectories from childhood to young adulthood associated with cardiovascular risk: results from the 23-year longitudinal Georgia Stress and Heart Study. Hypertension 2017; 69: 435-42.
    1. Boyer BP, Nelson JA, Holub SC. Childhood body mass index trajectories predicting cardiovascular risk in adolescence. J. Adolesc. Health 2015; 56: 599-605.
    1. Islam MT, Moller J, Zhou X, Liang Y. Life-course trajectories of body mass index and subsequent cardiovascular risk among Chinese population. PLoS One 2019; 14: e0223778.
    1. Oluwagbemigun K, Buyken AE, Alexy U, Schmid M, Herder C, Nothlings U. Developmental trajectories of body mass index from childhood into late adolescence and subsequent late adolescence-young adulthood cardiometabolic risk markers. Cardiovasc. Diabetol. 2019; 18: 9.
    1. Tengvall S, Ohlsson C, Bygdell M, Martikainen J, Andersson A, Kindblom JM. Pubertal-onset overweight and COPD in men: a cohort study. ERJ Open Res. 2020; 6: 00326-2019.
    1. Peralta GP, Fuertes E, Granell R, Mahmoud O, Roda C, Serra I, Jarvis D, Henderson J, Garcia-Aymerich J. Childhood body composition trajectories and adolescent lung function. Findings from the ALSPAC study. Am. J. Respir. Crit. Care Med. 2019; 200: 75-83.
    1. Gu S, Li R, Leader JK, Zheng B, Bon J, Gur D, Sciurba F, Jin C, Pu J. Obesity and extent of emphysema depicted at CT. Clin. Radiol. 2015; 70: e14-9.
    1. Sahebjami H, Domino M. Effects of starvation and refeeding on elastase-induced emphysema. J. Appl. Physiol. (1985) 1989; 66: 2611-6.
    1. Sahebjami H, MacGee J. Changes in connective tissue composition of the lung in starvation and refeeding. Am. Rev. Respir. Dis. 1983; 128: 644-7.
    1. Fliederbaum J, Heller A, Zweibaun K, Zarchi J. Clinical aspects of hunger disease in adults. Curr. Concepts Nutr. 1979; 7: 11-43.
    1. Vanfleteren L, Slebos DJ. The fat lady sings again. Respiration 2017; 94: 488-90.
    1. Oh W, Kim E, Castro MR, Caraballo PJ, Kumar V, Steinbach MS, Simon GJ. Type 2 diabetes mellitus trajectories and associated risks. Big Data 2016; 4: 25-30.
    1. Mortby ME, Janke AL, Anstey KJ, Sachdev PS, Cherbuin N. High "normal" blood glucose is associated with decreased brain volume and cognitive performance in the 60s: the PATH through life study. PLoS One 2013; 8: e73697.
    1. Heianza Y, Arase Y, Fujihara K, Hsieh SD, Saito K, Tsuji H, Kodama S, Yahagi N, Shimano H, Yamada N et al. Longitudinal trajectories of HbA1c and fasting plasma glucose levels during the development of type 2 diabetes: the Toranomon Hospital Health Management Center Study 7 (TOPICS 7). Diabetes Care 2012; 35: 1050-2.
    1. Bancks MP, Carnethon MR, Chow LS, Gidding SS, Jacobs DR Jr, Kishi S, Lima J, Lloyd-Jones D, Reis JP, Schreiner PJ et al. Fasting glucose and insulin resistance trajectories during young adulthood and mid-life cardiac structure and function. J. Diabetes Complications 2019; 33: 356-62.
    1. van den Borst B, Gosker HR, Zeegers MP, Schols AM. Pulmonary function in diabetes: a metaanalysis. Chest 2010; 138: 393-406.
    1. Anik A, Anik A, Uysal P. Assessment of pulmonary function by impulse oscillometry and spirometry in children with type 1 diabetes mellitus. Pediatr. Pulmonol. 2020; 55: 3517-24.
    1. Luyckx VA, Brenner BM. Low birth weight, nephron number, and kidney disease. Kidney Int. Suppl. 2005; 68: S68-77.
    1. Triest FJJ, Franssen FME, Reynaert N, Gaffron S, Spruit MA, Janssen DJA, Rutten EPA, Wouters EFM, Vanfleteren L. Disease-specific comorbidity clusters in COPD and accelerated aging. J. Clin. Med. 2019; 8: 511.
    1. Deo RC. Machine learning in medicine. Circulation 2015; 132: 1920-30.
    1. Prados-Torres A, Calderon-Larranaga A, Hancco-Saavedra J, Poblador-Plou B, van den Akker M. Multimorbidity patterns: a systematic review. J. Clin. Epidemiol. 2014; 67: 254-66.
    1. Vetrano DL, Roso-Llorach A, Fernandez S, Guisado-Clavero M, Violan C, Onder G, Fratiglioni L, Calderon-Larranaga A, Marengoni A. Twelve-year clinical trajectories of multimorbidity in a population of older adults. Nat. Commun. 2020; 11: 3223.
    1. Jensen AB, Moseley PL, Oprea TI, Ellesoe SG, Eriksson R, Schmock H, Jensen PB, Jensen LJ, Brunak S. Temporal disease trajectories condensed from population-wide registry data covering 6.2 million patients. Nat. Commun. 2014; 5: 4022.
    1. Khanolkar A, Patalay P. Clustering & trajectories of multimorbidity across the lifecourse: a 70 year birth cohort study. Eur. J. Public Health 2019; 29: ckz186.228. DOI: 10.1093/eurpub/ckz186.228

Source: PubMed

3
구독하다